Since complete loss of PPARγ signaling in clinicalbreast tumors seems to be a rare event [37], it is likely that patientsundergoing chronic treatment with chemical ligands for PPARγ will experiencealteration in the behavior of both breast carcinoma cells and their normalcounterparts. The gene discussed is PPARG; the disease is breast carcinoma.